Fig 1: See also Supplementary Figure S3 Caspase-11 synergizes with MT3 in impairing bacterial clearance. WT, Casp-11-/- , Mt3-/- and Casp-11-/-Mt3-/- mice were infected i.p. with E. coli (1 X109 CFUs/mouse) for 6h. (A) Bacterial CFUs measured in kidney, blood and peritoneal lavage, n = 3-6 per group, one-way ANOVA. (B) Western blots of pro-GSDMD, active-GSDMD (p31), pro-caspase-1, active-caspase-1, pro-IL1ß and active-IL-1ß in kidney homogenates, n = 3-6 per group, one-way ANOVA, data are mean ± SEM. (C) WT and Mt3-/- mice treated i.p. with MCC950 (1 mg/mouse) or PBS and infected i.p. with E. coli (1 X109 CFUs/mouse) for 6h. IL1ß was measured by ELISA in peritoneal lavage, n = 6 per group, one-way ANOVA, data are mean ± SEM. Bacterial CFUs in whole blood and kidney, n = 4 per group, one-way ANOVA, data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig 2: Caspase-11 significantly contributes to maintaining dual fuel bioenergetics- glycolysis and OXPHOS in macrophages potentially for cholesterol synthesis and trained immunity. Bone marrow macrophages were isolated from 3 WT and 3 Casp11–/– mice and treated with palmitic acid (500 µM) for 8 hours then pulled for seahorse analysis. (A) Seahorse XF96 Extracellular Flux Analyzer to measure extracellular acidification rate (glycolysis) of Casp11–/– vs WT BMDMs in palmitic acid supplemented medium. (B) Seahorse mitochondrial function assay of Casp11–/– vs WT BMDMs in palmitic acid supplemented medium.*P < 0.0, ****p < 0.0001.
Supplier Page from Thermo Fisher Scientific for Caspase 11 Antibody